Publication Year: 2010
-
The proteomic classifier VeriStrat identifies advanced non-small cell lung cancer (NSCLC) patients gaining clinical benefit from treatment with first line sorafenib and erlotinib
-
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
-
Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients
-
Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503